Synergistic Effects of CD40 Agonist Antibody and DC-Derived Exosomes Enhance Anti-Tumor Efficacy by Modulating the Tumor Microenvironment and Reducing Metastasis in a Murine Melanoma Model

被引：0
|
作者：
Gaur, Vidit
Bhattacharyya, Jayanta
机构：
来源：
CANCER IMMUNOLOGY RESEARCH | 2025年 / 13卷 / 02期
关键词：
D O I：
10.1158/2326-6074.IO2025-A106
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A106
引用
收藏
页数：2
相关论文
共 21 条
  • [1] Synergistic Anti-Tumor Efficacy of Toll-like Receptor and CD40 Stimulation with an Immunogenic Neoantigen Vaccine
    Hoki, T.
    Yamauchi, T.
    Eppolito, C.
    Francois, A. J.
    Odunsi, K.
    Ito, F.
    ANNALS OF SURGICAL ONCOLOGY, 2018, 25 : S148 - S148
  • [2] Agonist CD40 engineered smart immunosomes induced anti-tumor immunity, reduced associated toxicities and showed tumor free survival in murine glioblastoma model
    Gaur, Vidit
    Tyagi, Witty
    Das, Sanjeev
    Ganguly, Surajit
    Bhattacharyya, Jayanta
    CANCER RESEARCH, 2024, 84 (06)
  • [3] AJ17 potentiates agonist CD40 antibody efficacy and attenuates agonist CD40 induced PD-L1 expression and associated toxicity in murine tumor models
    Gaur, Vidit
    Barnwal, Anjali
    Ateeq, Bushra
    Bhattacharyya, Jayanta
    CANCER RESEARCH, 2023, 83 (07)
  • [4] A BISPECIFIC ANTIBODY TARGETING CD40 AND EPCAM INDUCES SUPERIOR ANTI-TUMOR EFFECTS COMPARED TO THE COMBINATION OF THE MONOSPECIFIC ANTIBODIES
    Ellmark, Peter
    Hagerbrand, Karin
    Levin, Mattias
    Von Schantz, Laura
    Deronic, Adnan
    Varas, Laura
    Sall, Anna
    Barchan, Karin
    Werchau, Doreen
    Ljug, Lill
    Thageson, Mia
    Rosen, Anna
    Sakellariou, Christina
    Lindstedt, Malin
    Ellmark, Peter
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A511 - A511
  • [5] Novel combination immunotherapy for pancreatic cancer: potent anti-tumor effects with CD40 agonist and interleukin-15 treatment
    Van Audenaerde, Jonas R. M.
    Marcq, Elly
    von Scheidt, Bianca
    Davey, Ashleigh S.
    Oliver, Amanda J.
    De Waele, Jorrit
    Quatannens, Delphine
    Van Loenhout, Jinthe
    Pauwels, Patrick
    Roeyen, Geert
    Lardon, Filip
    Slaney, Clare Y.
    Peeters, Marc
    Kershaw, Michael H.
    Darcy, Phillip K.
    Smits, Evelien L. J. M.
    CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2020, 9 (08)
  • [6] Synergistic anti-tumor effects of oncolytic virus and anti-programmed cell death protein 1 antibody combination therapy: For suppression of lymph node and distant metastasis in a murine melanoma model
    Sasaki, Yuki
    Maeda, Taku
    Hojo, Masahiro
    Miura, Takahiro
    Ishikawa, Kosuke
    Funayama, Emi
    Okada, Kazufumi
    Yamamoto, Yuhei
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2024, 740
  • [7] Agonistic Anti-CD40 Antibody Therapy is Effective Against Postoperative Cancer Recurrence and Metastasis in a Murine Tumor Model
    Khong, Andrea
    Brown, Matthew D.
    Vivian, Justin B.
    Robinson, Bruce W. S.
    Currie, Andrew J.
    JOURNAL OF IMMUNOTHERAPY, 2013, 36 (07) : 365 - 372
  • [8] The anti-tumor effects of CT-26 derived exosomes enriched by MicroRNA-34a on murine model of colorectal cancer
    Hosseini, Maryam
    Baghaei, Kaveh
    Hajivalili, Mahsa
    Zali, Mohammad Reza
    Ebtekar, Masoumeh
    Amani, Davar
    LIFE SCIENCES, 2022, 290
  • [9] The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice
    Gladue, Ronald P.
    Paradis, Timothy
    Cole, Susan H.
    Donovan, Carol
    Nelson, Robin
    Alpert, Robbin
    Gardner, Joe
    Natoli, Ed
    Elliott, Eileen
    Shepard, Richard
    Bedian, Vahe
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2011, 60 (07) : 1009 - 1017
  • [10] Synergistic anti-tumor efficacy of combined TLR3 and CD40 neoantigen vaccine requires Batf3-dependent dendritic cells
    Hoki, Toshifumi
    Yamauchi, Takayoshi
    Odunsi, Kunle
    Ito, Fumito
    JOURNAL OF IMMUNOLOGY, 2018, 200 (01):
123